RASBURICASE

It is a recombinant urate-oxidase produced by a genetically modified Saccharomyces cerevisiae strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus. It is used in combination with xanthine oxidase inhibitors in the therapy of severe hyperuricemia due to tumor lysis syndrome after initiation of cancer chemotherapy in treatment of malignant diseases.

Indications

It is used to treat or prevent high uric acid levels during chemotherapy.

Dosage

IV; 0.2 mg/kg as a 30 minute intravenous infusion daily for up to 5 days.

Contra-Indications

individuals deficient in glucose-6-phosphate dehydrogenase, hypersensitivity to rasburicase.

Special Precautions

Paediatric: Use with caution. Pregnancy: category C. Lactation: Not known if excreted in the human milk. Elderly: Use with caution.

Side Effects

anaphylaxis, Hemolysis, methemoglobinemia, nausea, vomiting, diarrhea, anxiety, stomach pain, mouth sores, throat pain, fever, headache, swelling of the hands, feet, ankles, or lower legs.

Drug Interactions

Data not sufficient.